Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of specialty biotechnology firm Santarus (NAS: SNTS) have had a wild ride today with its shares losing as much as 34% earlier this morning after reporting its second-quarter earnings results.
So what: For the quarter, Santarus reported a 77% increase in revenue to $47.2 million while net income grew 27% to $3.4 million, or $0.05 per share. Unfortunately, Santarus' profits fell $0.03 shy of what Wall Street had expected despite the robust growth. Santarus' guidance calls for the company to hit about $200 million in revenue in fiscal 2012, which is in line with the Street's forecast, and net income of $8 million to $11 million, or what amounts to $0.13 to $0.18 in EPS, more or less in line with analysts' current range of $0.15 to $0.18.
Now what: it's still early in the game, but Santarus showed remarkable growth for its three commercial drugs. Diet-control drugs Glumetza and Cycloset, targeted at type 2 diabetes patients, saw total prescriptions increase by 34% and 100%, respectively, while Fenoglide, which assists in cholesterol reduction, had growth of 17% in total prescriptions. In addition to these commercial drugs, Santarus submitted a new drug application for its ulcerative colitis drug, Uceris, and has multiple other clinical phase trials under way. Personally, I see today's earnings miss and drop as an overreaction and would take a much closer look at Santarus as a potential buy.
Craving more input? Start by adding Santarus to your free and personalized watchlist so you can keep up on the latest news with the company.
The article Why Santarus' Shares Plunged originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.